200 results about "Gene deletion" patented technology

The invention relates to the technical field of gene knockout, and particularly discloses a method for breeding a tcf25 gene deletion type zebra fish through gene knockout. The method comprises the steps of through a CRISPR/Cas9 gene editing technology, designing an appropriate targeting gene locus on a tcf25 gene of the zebra fish, synthesizing in vitro to obtain specific sgRNA and Cas9-mRNA, microinjecting into a cell of the zebra fish, and after culturing an embryo for 60h, selecting the embryo for carrying out genotyping, so that the effectiveness of the selected locus is verified. The method provided by the invention is lower in off-target rate, removes the tcf25 gene through interference, is beneficial to further revealing the whole process of cardiac morphogenesis and a molecular mechanism regulating the process through researching functions through a genetics means, and is of great importance on understanding a cardiac disease pathology and researching and developing a new therapeutic schedule medically.

The invention discloses a bacillus licheniformis host bacterium BL10 with multiple gene deletion, the accession number of which is CCTCCNO:M2013400. The host bacterium derives from a bacillus licheniformis WX-02 which partially or completely has deletion of ten genes. The ten genes comprises eight protease genes (mpr encoding a metalloprotease; vpr encoding a serine protease; aprX encoding an intracellular serine protease; epr encoding a minimal extracellular protease; bpr encoding a bacillus peptidase F; wprA encoding a protease combined with cell walls; aprE encoding an extracellular alkaline serine protease; and bprA encoding a bacillus peptidase F) and two extracellular secretory protein genes (hag encoding flagellin; and amyL encoding alpha-amylase). The BL10 has completely no extracellular protease activity and can reduce the degradation effect of a protease on a target protein. When the target protein is expressed by the expression host, the expression level is higher, and the host bacterium benefits protein expression enhancement.

The invention relates to a gene deletion system for the security control of transgene monocotyledon, comprising two homodromous loxP and FRT fused specificity recognition sites loxP-FRT, wherein a section of multiple clone site sequence for inserting a target gene to be led in plant is contained between the two specificity recognition sites. The gene deletion system can completely delete foreign genes in a specific plant organ by a plant expression vector which is formed by leading a monocotyledon tissue-specific promoter sequence, and can achieve the deletion efficiency of 99.8 percent, thereby being used for preparing the safe transgene monocotyledon.

This invention relates to test kit and method for detecting male Y chromosome microdeletion genes. The test kit contains 30 primers for amplifying AZF of Y chromosome, and 2 primers for amplifying male-specific Sry gene. The test kit can be used for detecting male Y chromosome microdeletion genes, and has such advantages as high efficiency, low cost and stable result.

The invention discloses a triple PCR detection primer set for rapidly distinguishing African swine fever virus wild strains from CD2V and/or 360-505R gene deletion strains. Nucleotide sequences of three pairs of detection primers are as shown in SEQ ID NO: 1-6. Three pairs of primers are utilized to amplify three genes of African swine fever viruses CD2V, P72 and 360-505R at a time, so that the detection cost for identifying different genes is reduced, and the detection time for identifying different genes is shortened; and moreover, three genes with different lengths can be amplified only byone-time PCR reaction, and whether gene deletion exists in the strains or not can be distinguished. The three genes can be identified by one-time PCR amplification only, the cost is reduced by about 2/3 for a traditional method for respectively amplifying and detecting the samples of the three genes, and the triple PCR detection primer set for rapidly distinguishing the African swine fever virus wild strains from the CD2V and/or 360-505R gene deletion strains has wide market prospect.

The use of a means to vary Ubc4p or Ubc5p activity in a fungal cell to control the copy number of a plasmid in the cell. The level of Ubc4p or Ubc5p activity may be reduced/abolished (for example by gene deletion, mutagenesis to provide a less active protein, production of antisense mRNA or production of competitive peptides) to raise the copy number and increase yield of a protein encoded by the plasmid.

The invention discloses a triple fluorescent quantitative PCR detection material and kit for distinguishing African swine fever virus wild strains from CD2V and/or 360-505R gene deleted strains. The detection material comprises primers and probes, and the nucleotide sequences are shown as SEQ ID NO: 1-9. According to the invention, triple fluorescent quantitative PCR amplification is carried out on African swine fever virus P72, CD2V and 360-505R genes by utilizing three groups of primer probes, so that the detection cost and the detection time for identifying different genes are reduced; whether gene deletion exists in the strain or not can be distinguished; the detection material and kit have high specificity and sensitivity; and for traditional qPCR enabling only one gene to be amplified each time, the provided mode has the following advantages: three genes are amplified at the same time in each PCR reaction, and the cost is reduced by about 2/3.

The invention discloses a porcine pseudorabies virus gene deletion attenuated vaccine strain for passage via low temperature of a cell and attenuation via drug screening and an application thereof. The attenuated vaccine strain is prepared through the following steps: based on a porcine pseudorabies virus variant strain (named as strain HeN1, of which the microbial preservation serial No. is CGMCC No. 6656), firstly, carrying out low-temperature passage and screening on a Vero cell to obtain large fragments of deleted viruses including gI, gE, Us9, Us2 and part of inverted repeated sequence which exist in zone US through, and then making the TK gene thereof partially deleted through drug screening. The gene-deleted attenuated vaccine strain is named as strain PRV TP, of which the microbial preservation serial No. is CGMCC No. 12300. A live vaccine or an inactivated vaccine (a single vaccine or combined vaccine) can be prepared from the attenuated vaccine strain disclosed by the invention, and can prevent porcine pseudorabies effectively, and a reagent for diagnosing or treating porcine pseudorabies can be prepared from the attenuated vaccine strain too. According to the porcine pseudorabies virus gene deletion attenuated vaccine strain for passage via low temperature of a cell and attenuation via drug screening and the application thereof, the porcine pseudorabies attenuated vaccine strain PRV TP has the advantages of good safety, efficient protection, convenient differential diagnosis and the like.

The invention discloses a chicken Marek's disease (MD) Meq gene deleted vaccine strain, a construction method thereof, and an application thereof. The chicken Marek's disease rMS delta Meq gene deleted vaccine strain has a microbe reservation number of CGMCC No. 4612. According to the invention, on a basis of a parent strain which is MDV MS strain, a 468bp base sequence on a front part of a main oncogene is deleted thorough two times of homologous recombination, such that the chicken Marek's disease Meq gene deleted vaccine strain is obtained. The invention also relates to the application of the gene deleted vaccine strain in preparation of medicine used for controlling chicken Marek's disease, and in detection and disgnosis methods used for distinguishing a vaccine strain and a chicken Marek's disease wild strain, wherein the methods are designed aiming at the deleted gene sequence of the gene deleted strain. The gene deleted vaccine strain provided by the invention has good safety and good immuno-protection effect upon chicken Marek's diseases. The vaccine strain can be used for preparing monovalent vaccines or combined vaccines used for controlling chicken Marek's disease.

The invention discloses food grade lactic acid bacteria active carrier Group A rotavirus vaccine and a preparation method thereof. The food grade lactic acid bacteria active carrier Group A rotavirus vaccine is characterized in that VP6 antigen protein from Group A virus, common serotype VP7 antigen protein (P serotype) and VP4 antigen protein (G serotype-expressed separately in the form of VP5* and VP8* protein subunit), vaccine adjuvant escherichia coli thermal unstable toxin B (LTB) and cholera toxin subunit B (CTB) are expressed and secreted by thyA gene deletion lactic acid bacteria cell or shown by the cell wall. Expressions of antigen protein and vaccine adjuvant protein are controlled by inducible or constitutive promoter, protein expression cassette is integrated onto the chromosome of the expression host lactic acid bacteria strain, and external antibiotics resistance gene introduced in gene manipulation is removed. The lactic acid bacteria active carrier rotavirus vaccine has the advantages of having wide serotype covering range, being easy to produce in large scale, and being safe and convenient to use without a refrigerator and a needle tubing.

The invention discloses a recombinant oncolytic vaccinia virus and a preparation method and application thereof. The thymidine kinase (TK) region of the virus comprises a coding sequence of a PD1 full-length antibody shown in the formula of SEQ ID NO.1. Through effective combination of the anti-tumor effect of gene therapy and the oncolytic effect of virus treatment, the oncolytic vaccinia virus for efficiently expressing the PD1 full-length antibody gene is prepared. When the oncolytic vaccinia virus produces the oncolytic effect of splitting tumor cells, the PD1 full-length antibody is efficiently expressed, the activity of PD1 on the surfaces of T cells is inhibited, the T cell immune response is activated and the dual antitumor effects are produced. Compared with the single gene therapy or viral therapy, the method using the recombinant oncolytic vaccinia virus improves the effects of killing malignant B cell lymphoma. Through virus replication-related gene deletion, the TK regionof the vaccinia virus genome is deleted so that specific replication of the viruses in the abnormally proliferating tumor cells is ensured and the viruses can not replicate in normal cells, so that the safety of the oncolytic vaccinia virus vector is greatly improved.

The invention discloses a watermelon oxysporum pathogenic FonAGL3 gene as well as a deleted DNA fragment, a deletion mutant and application thereof, and aims to solve the technical problem of biological prevention and treatment on watermelon oxysporum. A pathogenic gene FonAGL3 derived from watermelon fusarium oxysporum is analyzed and screened by inserting watermelon oxysporum T-DNA into a mutant library, by utilizing the homologous gene replacement principle, DNA fragments of the target gene FonAGL3 are replaced by gene DNA fragments of a resistance gene hygromycin B (HPH), a FonAGL3 gene deletion mutant is obtained by establishing a gene deletion carrier and implementing genetic transformation of a wild strain FON-11-06, and the FonAGL3 mutant bacterium has a good wilt prevention and treatment effect and is environmental-friendly and low in prevention and treatment cost.

The invention relates to a Brucella vaccine, in particular to the molecular marker and virulence gene deletion of Brucella vaccine strain. The study uses luciferase modified gene (Luc NF plus) to replace the partial fragment of Bp26 gene of Brucella attenuated vaccine S19 strain by constructing suicide plasmid and adopting the method of targeted homologous recombination (gene targeting), so as to damage the expression of the immunogenicity protein BP26 and construct the gene deletion mutant strain Delta S19-1 of the Brucella Bp26. The BMP18 protein is one of the main virulence factors of Brucella. The invention adopts the same method to exclude the Bmp 18 gene of Delta S19-1, so as to lead the Delta S19-1 not to express the Bmp 18 protein and the Brucella virulence gene deletion mutant strain Delta S19-2 is constructed. The invention solves the problems that the conventional Brucella vaccine can not distinguish between the artificial immunization and the wild bacteria infection of people and animals, the virus is strong and the vaccine is easy to cause the illness of inoculated people and animals. The invention has important significance and practical application value of the monitoring, diagnosis, purification and all the controls of Brucella.

The invention discloses a kit for simultaneously detecting multisite mutation of genes CYP2C19 and CYP2D6. A group of Taqman allele resolution analysis method-based specific primers and probes is obtained by meticulous designing, multiple verification, screening and optimization, and 8 functional variations of 4 types, i.e. single base displacement, deletion mutation, gene deletion and duplication mutation, of genes CYP2C19 and CYP2D6 can be detected; from DNA extraction to fluorescent PCR and then to result acquisition, 4 hours is required only, and the manual operation time is shorter than 2 hours. The kit containing the primers has the advantages of time saving, convenience, high sensitivity, capability of ensuring that the positive coincidence rate and negative coincidence rate of a sample are both over 99 percent, and the like.

The invention provides a detection method for deletion and insertion mutation of L367fs*46 (c.1179-1230del) and K385fs*4(c.1234-1235insTTGTC) of the ninth exon of a CALR (Calreticulin) gene. Universal amplification primers are designed according to deletion and insertion mutation areas of the ninth exon of the CALR gene, specific detection fluorescence probes are designed according to amplified fragments, real-time fluorescence quantification PCR (polymerase chain reaction) is performed on a to-be-detected sample, and deletion and insertion mutation of the CALR gene are identified through multiple single-tube reactions. The invention further provides applications of the universal amplification primers and the specific detection fluorescence probes in preparation of myeloproliferative neoplasm detection reagents as well as a kit for detecting myeloproliferative neoplasms.

The invention relates to a LAMP kit for detecting PRV, an establishment method and an application thereof. The kit comprises a detection system consisting of LAMP reaction solution of four primers. Detection has verified that the kit can quickly and conveniently detect the PRV with high efficiency, high specificity and high sensitivity under 60 to 65DEG C isothermal condition, does not need any complicated instrument, can well meet the requirement on the field detection to the PRV, can distinguish PRV gE gene deletion vaccine and field strains, provides a novel technical platform for the safety detection of food, can well meet the urgent need on the field detection of the PRV, is used for the field detection of import and export quarantine, food health departments, livestock farms and the like, and is easy to be popularized and applied in a large scope.

A method for detecting large rearrangements in BRCA1 and BRCA2 genes includes amplifying a nucleic acid sample in the presence of a primer pool to produce amplicons, where the primer pool includes target specific primers targeting regions of exons of the BRCA1 and BRCA2 genes. The method further includes sequencing the amplicons to generate a plurality of reads, mapping the reads to a reference sequence, determining a number of reads per amplicon for the amplicons associated with the exons of the BRCA and the BRCA2 genes, determining exon copy numbers for the exons of the BRCA1 and BRCA2 genes based on the number of reads per amplicon, detecting an exon deletion or duplication based on the exon copy numbers, and detecting a whole gene deletion of the BRCA1 or BRCA2 gene based on the number of reads per amplicon associated with the exons of the BRCA1 and BRCA2 genes.